Numbers and cellular origin of microparticles with surface-bound C3 or C9 in plasma from HUS patients
| . | CD42b-positive microparticles, 103/mL . | CD38-positive microparticles, 103/mL . | CD66-positive microparticles, 103/mL . | |||
|---|---|---|---|---|---|---|
| C3-positive . | C9-positive . | C3-positive . | C9-positive . | C3-positive . | C9-positive . | |
| Acute phase (n = 12) | 818* (552-1001) | 780* (654-1031) | 83† (48-128) | 84† (50-124) | 1.8* (1.3-2.5) | 1.5* (1.1-2.4) |
| Recovery (n = 12) | 64 (15-342) | 28 (11-258) | 35 (8-285) | 36 (10-304) | 0.2 (0.1-0.4) | 0.2 (0.1-0.6) |
| Pediatric controls (n = 6) | 73 (54-271) | 69 (55-284) | 48 (17-216) | 38 (15-202) | 0.3 (0.1-0.6) | 0.4 (0.2-0.7) |
| Renal failure controls (n = 3) | 65 (35-132) | 52 (10-109) | 41 (18-198) | 38 (7-124) | 5 (2-133) | 2.7 (2-93) |
| . | CD42b-positive microparticles, 103/mL . | CD38-positive microparticles, 103/mL . | CD66-positive microparticles, 103/mL . | |||
|---|---|---|---|---|---|---|
| C3-positive . | C9-positive . | C3-positive . | C9-positive . | C3-positive . | C9-positive . | |
| Acute phase (n = 12) | 818* (552-1001) | 780* (654-1031) | 83† (48-128) | 84† (50-124) | 1.8* (1.3-2.5) | 1.5* (1.1-2.4) |
| Recovery (n = 12) | 64 (15-342) | 28 (11-258) | 35 (8-285) | 36 (10-304) | 0.2 (0.1-0.4) | 0.2 (0.1-0.6) |
| Pediatric controls (n = 6) | 73 (54-271) | 69 (55-284) | 48 (17-216) | 38 (15-202) | 0.3 (0.1-0.6) | 0.4 (0.2-0.7) |
| Renal failure controls (n = 3) | 65 (35-132) | 52 (10-109) | 41 (18-198) | 38 (7-124) | 5 (2-133) | 2.7 (2-93) |
Data are expressed as the median and range (in parentheses) of circulating microparticles positive for each membrane-specific marker per milliliter.
P < .001 and †P < .01 comparing microparticles in plasma from patients with pediatric controls.